跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
TARO-BORTEZOMIB - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
TARO-BORTEZOMIB
Authorized
STANDARD
TARO-BORTEZOMIB
Taro Pharmaceuticals Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
4e3139338c5fc10d
Company
Taro Pharmaceuticals Inc
Type
Standard
Approval Details
Approval Id
4e3139338c5fc10d
Drug Approval Canada Name
TARO-BORTEZOMIB
Product Name
TARO-BORTEZOMIB
Status
Marketed
Status Date
2022-07-18
Original Market Date
2022-07-18
Din
02511932
Drug Class
Human
Dosage Form
Powder For Solution
Route Of Administration
Intravenous , Subcutaneous
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L01XG01 BORTEZOMIB
Atc Name
l 01 xg 01
Aig Number
0150433002
Company Name
Taro Pharmaceuticals Inc
Company Address
130 East Drive, Brampton, Ontario, Canada, L6T 1C1
Company Detail Path
/organization/taro-pharmaceuticals-inc
Company Information
Pharmaceutical Company Name
Taro Pharmaceuticals Inc
Country Name
Canada
Province Name
Ontario
City Name
brampton,ontario,country_ca
Address
130 East Dr
Active Ingredients
BORTEZOMIB (BORTEZOMIB MANNITOL BORONIC ESTER)
2.5 MG / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
4e3139338c5fc10d
Type
Standard
Back to Health Canada Approvals